Global Drugs for Non-small Cell Lung Cancer Market Data Survey Report 2013-2025

Table of Contents

1 Global Market Overview

• 1.1 Scope of Statistics
  • 1.1.1 Scope of Products
  • 1.1.2 Scope of Manufacturers
  • 1.1.3 Scope of Application
  • 1.1.4 Scope of Type
  • 1.1.5 Scope of Regions/Countries
• 1.2 Global Market Size

2 Regional Market

• 2.1 Regional Production
• 2.2 Regional Demand
• 2.3 Regional Trade

3 Key Manufacturers

• 3.1 Bristol-Myers Squibb
  • 3.1.1 Company Information
  • 3.1.2 Product & Services
  • 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.1.4 Recent Development
• 3.2 GlaxoSmithKline
  • 3.2.1 Company Information
  • 3.2.2 Product & Services
  • 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.2.4 Recent Development
• 3.3 Menarini
  • 3.3.1 Company Information
  • 3.3.2 Product & Services
  • 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.3.4 Recent Development
• 3.4 Sanofi
  • 3.4.1 Company Information
  • 3.4.2 Product & Services
  • 3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.4.4 Recent Development
• 3.5 Ziopharm Oncology
  • 3.5.1 Company Information
  • 3.5.2 Product & Services
  • 3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.5.4 Recent Development
• 3.6 Alchemia
  • 3.6.1 Company Information
  • 3.6.2 Product & Services
  • 3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.6.4 Recent Development
• 3.7 Amgen
  • 3.7.1 Company Information
  • 3.7.2 Product & Services
  • 3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.7.4 Recent Development
• 3.8 Apotex
  • 3.8.1 Company Information
  • 3.8.2 Product & Services
  • 3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.8.4 Recent Development
• 3.9 BioMarin Pharmaceutical
  • 3.9.1 Company Information
  • 3.9.2 Product & Services
  • 3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.9.4 Recent Development
• 3.10 CellAct Pharma
  • 3.10.1 Company Information
  • 3.10.2 Product & Services
  • 3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.10.4 Recent Development
• 3.11 Cerulean Pharma
  • 3.11.1 Company Information
  • 3.11.2 Product & Services
  • 3.11.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.11.4 Recent Development
• 3.12 Cipla
  • 3.12.1 Company Information
  • 3.12.2 Product & Services
  • 3.12.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.12.4 Recent Development
• 3.13 Cornerstone Pharmaceuticals
  • 3.13.1 Company Information
  • 3.13.2 Product & Services
  • 3.13.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.13.4 Recent Development
• 3.14 Curis
  • 3.14.1 Company Information
  • 3.14.2 Product & Services
  • 3.14.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.14.4 Recent Development
• 3.15 CytRx
  • 3.15.1 Company Information
  • 3.15.2 Product & Services
  • 3.15.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.15.4 Recent Development
• 3.16 Eli Lilly
  • 3.16.1 Company Information
  • 3.16.2 Product & Services
  • 3.16.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.16.4 Recent Development
• 3.17 Exelixis
  • 3.17.1 Company Information
  • 3.17.2 Product & Services
  • 3.17.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.17.4 Recent Development
• 3.18 Fresenius Kabi
  • 3.18.1 Company Information
  • 3.18.2 Product & Services
  • 3.18.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.18.4 Recent Development
• 3.19 Genentech
  • 3.19.1 Company Information
  • 3.19.2 Product & Services
  • 3.19.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.19.4 Recent Development
• 3.20 Hikma Pharmaceuticals
  • 3.20.1 Company Information
  • 3.20.2 Product & Services
  • 3.20.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.20.4 Recent Development
• 3.21 Hospira
  • 3.21.1 Company Information
  • 3.21.2 Product & Services
  • 3.21.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.21.4 Recent Development
• 3.22 Intas Pharmaceuticals
  • 3.22.1 Company Information
  • 3.22.2 Product & Services
  • 3.22.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.22.4 Recent Development
• 3.23 Karyopharm Therapeutics
  • 3.23.1 Company Information
  • 3.23.2 Product & Services
  • 3.23.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.23.4 Recent Development
• 3.24 Kyowa Hakko Kirin
  • 3.24.1 Company Information
  • 3.24.2 Product & Services
  • 3.24.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.25 Ligand Pharmaceuticals
  • 3.25.1 Company Information
  • 3.25.2 Product & Services
  • 3.25.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

4 Major Application

• 4.1 Hospital
  • 4.1.1 Overview
  • 4.1.2 Hospital Market Size and Forecast
• 4.2 Clinic
  • 4.2.1 Overview
  • 4.2.2 Clinic Market Size and Forecast
• 4.3 Others
  • 4.3.1 Overview
  • 4.3.2 Others Market Size and Forecast

5 Market by Type

5.By Radiofrequency Ablation (RFA)

• 5.1 Radiofrequency Ablation (RFA)
  • 5.1.1 Overview
  • 5.1.2 Radiofrequency Ablation (RFA) Market Size and Forecast
• 5.2 Radiation Therapy
  • 5.2.1 Overview
  • 5.2.2 Radiation Therapy Market Size and Forecast
• 5.3 Chemotherapy
  • 5.3.1 Overview
  • 5.3.2 Chemotherapy Market Size and Forecast
• 5.4 Targeted Therapies
  • 5.4.1 Overview
  • 5.4.2 Targeted Therapies Market Size and Forecast
• 5.5 Immunotherapy
  • 5.5.1 Overview
  • 5.5.2 Immunotherapy Market Size and Forecast

6 Price Overview

• 6.1 Price by Manufacturers
• 6.2 Price by Application
• 6.3 Price by Type

7 Conclusion